First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer: A retrospective pooled analysis.

Authors

null

Pilar Garcia-Alfonso

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Pilar Garcia-Alfonso , Eduardo Diaz-Rubio , Albert Abad , Alfredo Carrato , Bartomeu Massuti , Rosa Rodríguez Alonso , Jose Luis Manzano , Andres J. Muñoz Martín , Gema Durán , Beatriz García de Paredes , Maria Jose Safont Aguilera , Reyes Ferreiro Monteagudo , Eva Martinez de Castro , Encarnación González Flores , Manuel Valladares-Ayerbes , Cristina Gravalos Castro , Vicente Alonso Orduña , Jose María Vieitez , Pilar Escudero , Enrique Aranda

Organizations

Hospital General Universitario Gregorio Marañón, Madrid, Spain, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), University Complutense, Madrid, Spain, CIBERONC, Madrid, Spain, Instituto Catalán de Oncología, Hospital Germans Trias i Pujol, Barcelona, Spain, IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal, Madrid, Spain, Alicante University Hospital ISABIAL, Alicante, Spain, IMIBIC, Hospital Universitario Reina Sofía, Córdoba; Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain, Instituto Catalán de Oncología, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, Hospital General Universitario Gregorio Marañón, Instituto Investigación Sanitaria Gregorio Marañón, Madrid, Spain, Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), CIBERONC, Madrid, Spain, Hospital General Universitario de Valencia, Valencia, Spain, Hospital Universitario Marqués de Valdecilla, Santander, Spain, H. Virgen de las Nieves, Granada, Spain, Complejo Hospitalario Universitario A Coruña, Instituto Investigación Biomédica INIBIC, A Coruña, Spain, Hospital Doce de Octubre, Madrid, Spain, Aragon Institute of Biomedical Research (IISA), Miguel Servet University Hospital, Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Zaragoza, Spain, Hospital Universitario Central de Asturias, Oviedo, Spain, Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III/ Spain, Córdoba, Spain

Research Funding

Pharmaceutical/Biotech Company
Roche Farma SA

Background: Biological agents, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding appropriate management of elderly patients with mCRC is lacking. This study compared the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods: This retrospective analysis used pooled data from five Spanish TTD collaborative group studies of adults with advanced CRC who received first-line treatment with bevacizumab, cetuximab or panitumumab, stratified by age (≥65 vs < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results: In total, 999 patients from five studies were included in the analysis; 480 (48%) were aged ≥65 years and 519 (52%) were aged < 65 years; 733 (73.37%) were treated with bevacizumab, 189 (18.92%) received cetuximab and 77 (7.71%) received panitumumab. Median PFS did not significantly differ between patients aged ≥65 versus < 65 years (9.9 vs 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88–1.17). Median OS was significantly shorter in older versus younger patients (21.3 vs 25.0 months; HR 1.21; 95% CI 1.04–1.41; P = 0.0132). There was no significant difference between older versus younger patients in ORR (59% vs 62%). Older patients experienced more treatment-related grade ≥3 adverse events. Conclusions: Biological agents are an effective first-line treatment option for elderly patients with mCRC, with comparable efficacy in PFS and ORR to that observed in younger patients and a manageable safety profile.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4017)

DOI

10.1200/JCO.2020.38.15_suppl.4017

Abstract #

4017

Poster Bd #

9

Abstract Disclosures